Howie, 1985 - Google Patents
The progestogen-only pillHowie, 1985
- Document ID
- 8964572947532305903
- Author
- Howie P
- Publication year
- Publication venue
- British journal of obstetrics and gynaecology
External Links
Snippet
PIP: This commentary reviews the indications for and side effects of the progestogen-only oral contraceptive (OC) pill, which accounts for under 3% of hormonal contraceptive sales in the UK. The progestogen-only pill has the advantage of fewer metabolic changes, a lower …
- 239000000583 progesterone congener 0 title abstract description 21
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
- A61F6/142—Wirelike structures, e.g. loops, rings, spirals
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2256977C (en) | Methods of extended use oral contraception | |
| Tyler | Current status of oral contraception | |
| Vorherr | Contraception after abortion and post partum: An evaluation of risks and benefits of oral contraceptives with emphasis on the relation of female sex hormones to thromboembolism and genital and breast cancer | |
| US4018919A (en) | Sequential contraceptive method using two types of progestational agents | |
| Howie | The progestogen-only pill | |
| Morris et al. | Post-coital oral contraception | |
| BACKER Jr | Isopregnenone (Duphaston*): A New Progestational Agent | |
| CA2392841A1 (en) | Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea | |
| Kupperman et al. | Induction of ovulation in the human: therapeutic and diagnostic importance | |
| RU2139055C1 (en) | Method of preventing and delaying fecundation | |
| Speroff | The formulation of oral contraceptives: does the amount of estrogen make any clinical difference? | |
| GB1253500A (en) | Method of contraception | |
| Mishell Jr | Current status of oral contraceptive steroids | |
| Goldzieher et al. | Seven years of clinical experience with a sequential oral contraceptive | |
| Szontagh et al. | Post-coital contraception with dienoestrol | |
| Smythe 2nd et al. | Ectopic pregnancy after postcoital diethylstilbestrol | |
| Hood et al. | Enovid therapy for premenstrual tension | |
| Roland | Wy 3707, a totally synthesized progestogen for contraception | |
| Karim et al. | Injectable steroids as a method of contraception | |
| Ruggiero | Prescription contraceptives: countering the risks | |
| Drife | The pill and the breast | |
| Greenblatt | Oral contraceptives: the state of the art | |
| Elstein | Low-dose progestagens as contraceptive agents | |
| WALLACH | Breast and reproductive system effects of oral contraceptives | |
| WG | THE DIFFICULTIES AND DANGERS OF ORAL CONTRACEPTION. |